» Articles » PMID: 39953811

Analysis of Two Neuroanatomical Subtypes of Parkinson's Disease and Their Motor Progression Based on Semi-Supervised Machine Learning

Overview
Specialties Neurology
Pharmacology
Date 2025 Feb 15
PMID 39953811
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The high heterogeneity of Parkinson's disease (PD) hinders personalized interventions. Brain structure reflects damage and neuroplasticity and is one of the biological bases of symptomatology. Subtyping PD in the framework of brain structure helps in the prediction of disease trajectories and optimizes treatment strategies.

Methods: The study included a total of 283 de novo PD and 141 healthy controls (HC). Structural heterogeneity between PD and HC was compared, and patients were classified using Heterogeneity through Discriminative Analysis. Gray matter volume (GMV), clinical symptoms, and substantia nigra free water (SNFW) among all subtypes were compared. These subtypes were followed for an average of 2.5 years to monitor motor impairment.

Results: Early PD patients possessed higher GMV heterogeneity than HC, and two subtypes based on GMV patterns were identified. Subtype 1 showed widespread GMV reductions, while subtype 2 had an increased volume in the basal ganglia and parts of the cortex. Subtype 1 had more severe motor and non-motor symptoms, as well as higher posterior SNFW. The whole-brain GMV in the PD group was negatively correlated with posterior SNFW; basal ganglia volume in subtype 1 was negatively correlated with Unified Parkinson's Disease Rating Scale (UPDRS)-III scores, whereas no linear correlation was found in subtype 2. The UPDRS-III progression rate was higher in subtype 1 than in subtype 2 (2.52 vs 0.92 points/year).

Conclusion: The heterogeneity of PD patients reflected the changes in their brain structure. The identification of these changes helps the classification of patients into different subtypes, additionally supported by clinical manifestations and SNFW, with consequent benefits for clinical consultancy and precision medicine.

References
1.
Geng D, Li Y, Zee C . Magnetic resonance imaging-based volumetric analysis of basal ganglia nuclei and substantia nigra in patients with Parkinson's disease. Neurosurgery. 2006; 58(2):256-62. DOI: 10.1227/01.NEU.0000194845.19462.7B. View

2.
Calabresi P, Mechelli A, Natale G, Volpicelli-Daley L, Di Lazzaro G, Ghiglieri V . Alpha-synuclein in Parkinson's disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis. 2023; 14(3):176. PMC: 9977911. DOI: 10.1038/s41419-023-05672-9. View

3.
Jellinger K . Is Braak staging valid for all types of Parkinson's disease?. J Neural Transm (Vienna). 2018; 126(4):423-431. DOI: 10.1007/s00702-018-1898-9. View

4.
Dennis E, Manza P, Volkow N . Socioeconomic status, BMI, and brain development in children. Transl Psychiatry. 2022; 12(1):33. PMC: 8786961. DOI: 10.1038/s41398-022-01779-3. View

5.
Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N . Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002; 15(1):273-89. DOI: 10.1006/nimg.2001.0978. View